Sanicet

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sanicet

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Oral tablet, Oral liquid, Injection
Pharmacological class Macrolide Antibiotic
Common use Fights bacterial infections
Origin Semisynthetic

What is Sanicet and What Type of Medicine is It?

Sanicet is a prescription-only medicine classified as a semisynthetic macrolide antibiotic, placing it within the therapeutic group of antiinfective agents. The core active ingredient, Clarithromycin, is the International Nonproprietary Name (INN) for the compound.

Clarithromycin functions as a protein synthesis inhibitor by selectively binding to the 50S ribosomal subunit of susceptible bacteria, which halts the assembly of the necessary proteins required for the organism to grow and multiply. This mechanism is recognized for its effectiveness in allowing the body to control and clear the infectious population. Macrolide antibiotics like this are agents used to manage infections across various body systems, providing a solution for bacterial invasion.

Composition, Origin, and Available Forms

The active substance, Clarithromycin (chemically, 6-O-methylerythromycin), confirms its semisynthetic origin through modification of the naturally occurring macrolide Erythromycin. This chemical alteration is a key differentiating feature, as pharmacological properties indicate it enhances the molecule's acid stability. This stability is critical for drug absorption following oral administration, ensuring the medicine can enter the bloodstream to target the infection.

Sanicet is supplied as a single active ingredient product in multiple pharmaceutical preparations to ensure flexibility in treatment, accommodating various patient needs and routes of administration. These forms include the standard oral tablet, the specialized extended-release tablet formulated for sustained delivery, and preparations such as granules or powder for suspension to create a liquid for patient groups who require non-solid oral forms. The availability of both immediate and extended-release forms provides clinical differentiation in how the active ingredient is delivered over time.

What side effects are possible with Sanicet?

Possible Side Effects and Safety Information

The safety profile of Sanicet (Clarithromycin) is defined by official regulatory documentation, which organizes adverse events by frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Officially Classified Adverse Reactions

Adverse reactions classified as Common (affecting 1 to 10 users in 100) frequently involve the gastrointestinal system, including diarrhoea, nausea, vomiting, abdominal pain, and dyspepsia. Within the neurological and psychiatric domains, headache, insomnia, and dysgeusia (taste change) are also commonly reported. Abnormal liver function test results are noted in this category.

Less common events may involve the blood and lymphatic system or lead to jaundice or anxiety. Gastrointestinal side effects may be more frequent at the start of treatment.

Documented Serious Safety Concerns

Official labeling specifies rare but critical safety events. Clarithromycin is associated with the risk of QT c interval prolongation, which can lead to life-threatening ventricular arrhythmias, including Torsades de pointes. Cases of severe hepatic failure and potentially fatal reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented. Additionally, the risk of developing Clostridium difficile-associated diarrhoea (CDAD) is noted, which can occur during or after treatment.

Population-Specific Safety Notes

The medicine is contraindicated in individuals with a history of QT prolongation or severe ventricular arrhythmia. It is also restricted for use in patients with severe hepatic failure combined with renal impairment, due to the risk of systemic accumulation and toxicity. Increased cardiotoxicity risk is observed in elderly patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Manifestations

Regulatory reports indicate that ingestion of large amounts of Sanicet (Clarithromycin) is primarily associated with the onset of pronounced gastrointestinal symptoms, including nausea, vomiting, abdominal pain, and diarrhea. In instances of significant overexposure, reports have documented more severe manifestations such as altered mental status, paranoid behavior, hypokalemia (low potassium), and hypoxemia (low blood oxygen). The potential for certain cardiac complications, particularly related to the prolongation of the QT interval, is a documented risk of the macrolide class.

When Immediate Medical Help Is Required

Immediate medical attention is required upon any suspicion of overdose. Official governmental guidance mandates contacting a Poison Control Centre or emergency services at once, particularly if the individual has collapsed, is having a seizure, is experiencing trouble breathing, or cannot be awakened.

Management and Limitations

Overdosage management is directed toward the prompt elimination of unabsorbed drug from the gastrointestinal tract and the provision of symptomatic and supportive measures for any resulting adverse reactions. Regulatory information explicitly notes that Clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis, which is an important consideration for treating acute toxicity.

Therapeutic Uses of Sanicet

What Sanicet Treats: Main Uses and Benefits

Sanicet (Clarithromycin) is used to address bacterial infections across several key domains, contributing to symptom management and functional recovery. It is generally used for mild to moderate infections caused by susceptible bacteria.


Therapeutic Scope and Symptom Relief

This medicine is commonly used in conditions presenting with acute episodes across the respiratory system, skin, and soft tissues. It helps manage symptom clusters that may become intense or disruptive, such as a severe cough, difficulties with breathing, elevated fever, pronounced pain, redness, and swelling.

Sanicet is relevant in clinical settings involving acute or unstable symptom patterns, including its use in managing symptoms associated with pneumonia, bronchitis, sinusitis, pharyngitis, cellulitis, and otitis media. It is also applied when appropriate as part of combination therapy to manage the bacterium associated with peptic ulcers and for specialized management of Mycobacterium avium Complex (MAC) infections in vulnerable patients. This therapeutic application contributes to easing the overall symptom burden and supports general well-being during symptomatic phases.

“This application supports a sense of stability by addressing the cause of recurrent or chronic conditions that can lead to significant functional strain.”

Domain Common Symptom Addressed Primary Therapeutic Benefit
Respiratory Severe cough, fever, breathing difficulty Supports easing the overall symptom burden
Skin/Tissue Localized pain, redness, swelling Helps maintain functional stability
Gastrointestinal Symptoms associated with peptic ulcer disease Assists with managing recurrent symptoms

Regulatory References

  1. Official FDA Drug Label for Clarithromycin

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sanicet — Official Regulatory Information

Sanicet (clarithromycin) is a prescription medicine with specific populations for whom use is contraindicated (prohibited) or requires caution, as stated in authoritative regulatory documents.


Populations Prohibited (Contraindicated)

Category Contraindication Criteria
Allergies Known hypersensitivity to clarithromycin, other macrolide antibiotics, or any of the product's excipients.
Cardiac Conditions History of QT prolongation (congenital or documented acquired) or ventricular cardiac arrhythmia, including torsades de pointes.
Physiological States Electrolyte disturbances (hypokalaemia or hypomagnesaemia).
Organ Impairment Severe hepatic failure combined with renal impairment.
Drug Interactions Concomitant use with specific medications: cisapride, pimozide, ergot alkaloids (e.g., ergotamine), lovastatin, simvastatin, lomitapide, lurasidone, oral midazolam, ticagrelor, ivabradine, or ranolazine.

Restricted or Cautionary Use

  • Pediatric Use: Safety and efficacy are not established for children younger than 6 months of age.
  • Existing Conditions: Caution is advised for patients with coronary artery disease, severe cardiac insufficiency, or moderate to severe renal impairment.
  • Pregnancy/Lactation: Prescribing to pregnant women, especially during the first trimester, requires careful weighing of risks and benefits; use during breastfeeding is based on an individual risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sanicet's official interaction profile is characterized by its function as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and its ability to inhibit the drug transporter P-glycoprotein (P-gp). These documented pharmacokinetic interactions lead to reduced clearance and increased plasma concentrations (exposure) of many co-administered medicinal products.

Formal Contraindications

Co-administration with several medicines is contraindicated due to the officially documented risk of serious toxicity. This includes Lovastatin and Simvastatin, due to the significant risk of myopathy and rhabdomyolysis from increased statin exposure. Other contraindicated substances are Pimozide, Astemizole, Cisapride, and Terfenadine, based on the established risk of serious cardiac arrhythmias like torsades de pointes.

Additionally, co-administration with Ergotamine and Dihydroergotamine is prohibited due to the risk of acute ergot toxicity, characterized by vasospasm and ischemia. The combination with Colchicine is contraindicated specifically in patients with underlying renal or hepatic impairment.

Significant Interaction Outcomes

Interactions with oral anticoagulants, such as Warfarin, are officially documented to carry a risk of serious hemorrhage and significant elevation in the International Normalized Ratio (INR). Sanicet may also lead to significant hypoglycemia when co-administered with certain oral hypoglycemic agents. For the extended-release tablet form, the regulatory label requires that it be taken with food to prevent a reduction in the drug’s plasma exposure.

Mechanism of Action

How Sanicet Works

Sanicet's mechanism is defined by the molecular inhibition of bacterial protein synthesis. Its active component, Clarithromycin, functions as a reversible inhibitor by selectively binding to the 50S ribosomal subunit of susceptible bacteria, specifically targeting the 23S rRNA within the ribosomal exit tunnel. This precise molecular interaction arrests the translocation step required for the continuation of peptide chain elongation. The resulting physiological effect is the suppression of microbial proliferation.

The drug's action is further enhanced by dual-active mechanistic amplification: its major metabolite, 14-OH Clarithromycin, retains the same ribosomal inhibitory mechanism. The co-existence of these two active compounds contributes to an additive or synergistic mechanistic effect against specific pathogens, resulting in effective saturation of the bacterial 50S targets. This dual activity results in modulation of the microbial population.

However, the drug's effect profile is subject to constraint by target modification. The physiological effect is constrained when bacteria utilize resistance mechanisms, such as the enzymatic methylation of the 23S rRNA, which physically blocks Clarithromycin from binding effectively, preventing molecular target saturation.

Dosage and Administration Information

How to Use Sanicet: Administration Guidelines

The following details the methods associated with the administration of Sanicet. It does not include therapeutic uses, benefits, or safety information.

Administration Scope

The approved routes of administration for Sanicet include Oral Use (for tablets and suspension) and Intravenous (IV) Infusion (for the powder for reconstitution).

Standard Dosing and Frequency:

The standard adult dosing schedule generally requires administration Twice Daily (BID). The amount is typically 500 mg per dose, but specific regimens may start at 250 mg. The duration of therapy often ranges from 7 to 14 days, which must be completed as written.

Special Instructions for Use:

  • Tablets: Must be swallowed whole. Tablets should not be crushed or chewed to maintain the integrity of the release mechanism.
  • IV Administration: Requires the powder to be reconstituted and then diluted. The infusion must be administered slowly, over a minimum duration (e.g., no less than 2 hours).
  • Food Timing: Sanicet may be taken without regard to meals unless specific formulations mandate administration with food to minimize gastric disturbance.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. If it is nearly time for the next scheduled dose, the missed dose should be skipped to prevent accidental doubling.

Population-Specific Rules

  • Pediatric Patients: For children under 12, the oral suspension form is the approved formulation, as tablets are deemed unsuitable.
  • Dose Adjustment: Patients with impaired renal function (creatinine clearance < 30 mL/min) are instructed to reduce the dose by one-half of the standard amount. This adjustment is intended to prevent accumulation.

Recent Clinical Evidence

Sanicet: Recent Clinical Evidence

Overview of Research Findings

Clinical trials examined whether the drug was associated with a change in symptoms for fibromyalgia. Large-scale Phase 3 trials evaluated whether the combination was associated with measurable outcomes in participants when compared to a placebo.

Research evaluated the drug's effect on neurotransmitter reuptake and explored whether this was associated with changes in central sensitization. Further analysis focused on whether changes in key neurotransmitter levels correlated with reported changes in pain and fatigue scores.

Studies examined whether pain scores showed a measured change during the first 48 hours of treatment. Data from the primary endpoint analysis indicated that the greatest difference from placebo was observed after 12 weeks of treatment.

Comparative Research and Secondary Outcomes

Phase 3 data evaluated whether the combination showed different outcomes when compared to existing monotherapies. The outcomes measured included changes in the mean daily pain score and participant-reported global impression of change.

Reported data included an assessment of tolerability and the frequency of side effects among the study participants. Researchers also evaluated whether quality of life scores showed a measurable change over the treatment period.

Research evaluated whether this treatment was associated with measurable outcomes in participants with refractory disease. Further studies are being conducted to confirm long-term outcomes and the drug’s potential association with changes in functional capacity.

Key Studies & References

  1. Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
  2. Fibromyalgia in adults: diagnostic management and treatment strategy - Haute Autorité de Santé (HAS) Guideline

Frequently Asked Questions (FAQ)

Common questions about Sanicet (FAQ)

Q: What happens if I miss taking Sanicet at the usual time?

Official administration instructions state that if a dose is missed, it can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the official guidance is to skip the missed dose entirely to prevent a double dose.

Q: Is it common to feel tired or dizzy when first starting Sanicet?

Regulatory safety information lists dizziness as a potential side effect. While not always classified as a common event, other symptoms like headache are frequently reported. Extreme tiredness or fatigue has also been reported in official safety reports.

Q: How long does Sanicet stay in your system after you stop taking it?

Pharmacokinetic studies describe how the body processes the medicine. The elimination half-life for the active component, Clarithromycin, is generally noted to be between 3 and 4.8 hours. For the active metabolite, 14-OH-Clarithromycin, the half-life is typically longer, ranging from approximately 5 to 8.7 hours.

Q: Is Sanicet known to affect driving or operating machinery?

Because Sanicet may cause side effects such as dizziness, confusion, or disorientation, official product information advises caution. Official guidance advises caution when driving or operating complex machinery until a patient knows how the medicine affects them.

Q: Are there any specific foods or drinks that should be avoided while using Sanicet?

The immediate-release forms of the drug can generally be taken without regard to meals. However, some studies have examined the potential for grapefruit juice to interact with this type of medication. The recommended approach is to follow the specific instructions provided for the exact formulation being used.

Q: What is the average duration of treatment with Sanicet?

For many of the common bacterial infections it is approved to treat, official product information describes the usual course of therapy as lasting between 7 and 14 days. The exact duration may vary based on the specific infection being treated.

Q: What is the function of the inactive ingredients in Sanicet?

All medicines contain active and inactive ingredients. Regulatory documents list the inactive ingredients, which are substances like cellulosic polymers or dyes. These are included to stabilize the medicine, ensure the active drug is properly delivered, and aid in the manufacturing of the specific dosage form.

Q: Is Sanicet used for anything other than its main approved condition?

Official indications confirm the drug is approved by regulatory bodies for a range of bacterial infections. These include infections affecting the skin, respiratory system (lungs, sinuses), and ears, as well as specific conditions like Mycobacterium avium complex (MAC) infection and H. pylori associated ulcers.

Q: Why is Sanicet sometimes compared to [Similar Drug Name]? (Placeholder)

Sanicet belongs to the pharmacological class known as macrolide antibiotics. Drugs that are classified in the same group often share a similar mechanism of action and are therefore frequently discussed together in the context of treating bacterial infections.

Q: What makes Sanicet different from other treatments for [Condition]? (Placeholder)

The active ingredient in Sanicet, Clarithromycin, is a semisynthetic macrolide that is a chemical modification of the drug Erythromycin. Regulatory documents confirm this modification enhances the molecule's stability in acid, which is an important factor for absorption when taken orally.

Q: Is Sanicet considered a narcotic or controlled substance?

Official drug classifications confirm that Sanicet (Clarithromycin) is categorized as a macrolide antibiotic. It requires a prescription, but it is not listed as a narcotic or a controlled substance by regulatory agencies.

Q: Can Sanicet be used by children or adolescents?

Official product labeling provides specific dosing information and approved formulations for pediatric patients generally starting from 6 months of age. Children under 12 typically use the oral suspension form. Dosing for adolescents is based on age and body weight, as defined in regulatory documents.

Q: Is Sanicet safe to use for people with kidney problems?

For patients with severe renal impairment, official guidelines state that the dose must be reduced to prevent the drug from building up in the body. Official prescribing information describes the medicine as contraindicated for use in patients who have severe hepatic failure combined with renal impairment.

Q: Does Sanicet have any known interaction with common over-the-counter pain relievers?

Regulatory documents primarily detail interactions with prescription medicines, particularly those affecting the CYP3A4 enzyme system. Official guidance encourages patients to inform their healthcare professional about all co-administered products, including over-the-counter pain relievers.

Q: Is it possible for Sanicet to cause a change in mood or behavior?

Official safety data lists several central nervous system effects reported by some users. These effects include anxiety, confusion, depression, and in rare cases, severe mood or mental changes and unusual behavior.

Q: What happens if I stop taking Sanicet suddenly?

Official guidance often highlights the risk that stopping treatment early may negatively impact the patient’s recovery or allow the underlying infection to return. Patients are generally advised that the full prescribed course of treatment is important.

Q: Is there a generic version of Sanicet available?

Yes, the active ingredient in Sanicet, Clarithromycin, is available in both brand-name products and in generic versions that have been approved by regulatory agencies.

Q: How does Sanicet affect sleep patterns?

Official safety information lists insomnia (difficulty sleeping) and nightmares as possible side effects. Other sleep disturbances, such as vivid dreams, have also been reported by users.

Q: Can Sanicet be taken while using herbal supplements?

Regulatory documentation and drug guidance often include a warning that Clarithromycin may interact negatively with some herbal remedies and complementary supplements. Official guidance suggests informing a doctor or pharmacist about the use of any herbal products or complementary supplements when taking this medication.

Q: Are there any warnings about using Sanicet during pregnancy or while breastfeeding?

Official documents advise that the use of Sanicet during pregnancy, especially in the first trimester, requires a careful evaluation of the benefits versus the potential risks. The drug is known to pass into breast milk, meaning use while breastfeeding must also be based on an individual risk assessment.

Q: What is the maximum amount of time a person should use Sanicet?

For many common infections, the typical course of treatment lasts 7 to 14 days. However, regulatory information notes that for specific, chronic infections, such as those caused by Mycobacterium avium complex (MAC), treatment may be continued long-term, provided clinical benefit is maintained.

Q: Is it normal to experience vivid dreams while taking Sanicet?

Sleep disturbances, including nightmares and vivid dreams, have been reported in post-marketing safety data collected from users of the medication.

Q: What is the most serious potential side effect described for Sanicet?

Official documentation identifies several rare but critical safety events. These include a risk of QTc interval prolongation, which can lead to life-threatening ventricular arrhythmias, as well as severe liver failure and severe, potentially fatal skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Q: Can Sanicet affect fertility in men or women?

Available clinical evidence and official guidance do not suggest that taking Sanicet reduces fertility or affects reproductive capacity in men or women.

Q: Is Sanicet available in different strengths?

Yes, official drug information confirms that Sanicet is available in multiple strengths to accommodate different dosing needs, such as 250 mg and 500 mg tablets, and various concentrations of the oral suspension.

Q: Can the effectiveness of Sanicet decrease over time?

Official regulatory documents acknowledge that bacterial resistance can develop. This occurs when bacteria change or adapt, preventing the drug from binding effectively, which can lead to a reduction in the treatment’s effectiveness.

Q: Is it true that Sanicet needs to be taken with food?

This depends on the specific formulation. The standard immediate-release tablets or suspension can usually be taken with or without food. However, the extended-release tablet formulation must be taken with food to ensure proper absorption.

Q: What are the known effects of Sanicet on blood sugar levels?

Official interaction profiles document a risk of significant hypoglycemia (dangerously low blood sugar) when Sanicet is taken concurrently with certain oral medicines prescribed to manage blood sugar.

How should Sanicet be stored and disposed of?

How to Store and Dispose of Sanicet (Clarithromycin)

The storage and disposal of Sanicet must comply strictly with official regulatory requirements to ensure product integrity and safety.

Storage Conditions

Sanicet tablets and the powder for suspension must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and moisture, and the container must be kept tightly closed in the original packaging.

For the reconstituted oral suspension, the medicine must not be refrigerated or stored below 5 C (41 F) and must be discarded after a limited shelf-life of 14 days.

Child Safety and Disposal

All forms of Sanicet must be stored out of the sight and reach of children.

Unused or expired product requires disposal according to local pharmaceutical requirements and must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sanicet found in:

A-Z Index: